Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19778388 | 0.81 | MAP2K7 (0.30) | MAP2K7HTTSMN1; SMN2 | |
| SCHEMBL2371337 | 0.76 | LMNA (0.39) | HTTSMN1; SMN2LMNA | |
| SCHEMBL11916225 | 0.76 | PDE10A (0.39) | LMNA | |
| SCHEMBL10267453 | 0.75 | NPSR1 (0.32) | MAP2K7 | |
| SCHEMBL12179644 | 0.74 | — | — | |
| SCHEMBL6671499 | 0.74 | ABCB1 (0.47) | HTTSMN1; SMN2LMNA | |
| SCHEMBL2775326 | 0.74 | LMNA (0.39) | HTTSMN1; SMN2LMNA | |
| SCHEMBL13828348 | 0.73 | ALDH1A1 (0.43) | HTTLMNA | |
| SCHEMBL27762225 | 0.73 | RXFP1 (0.39) | — | |
| SCHEMBL12303154 | 0.71 | PDK2 (0.36) | MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MAP2K7 1753/4885HTT 1365/4885SMN1; SMN2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.